Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351856 | 0.92 | DRD2 (0.55) | DRD2ACHEDRD3TACR1 | |
| SCHEMBL1350548 | 0.92 | DRD3 (0.44) | DRD2BCHEACHEBACE1DRD3 | |
| SCHEMBL1351093 | 0.92 | DRD3 (0.44) | DRD2BCHEACHEBACE1DRD3 | |
| SCHEMBL1350403 | 0.92 | DRD3 (0.44) | DRD2BCHEACHEBACE1DRD3 | |
| SCHEMBL1351531 | 0.91 | DRD2 (0.47) | DRD2BCHEACHEBACE1DRD3 | |
| SCHEMBL1351983 | 0.90 | DRD2 (0.47) | DRD2DRD4 | |
| SCHEMBL1351864 | 0.89 | SIGMAR1 (0.54) | DRD2BCHEACHEBACE1DRD4 | |
| SCHEMBL1351573 | 0.88 | LMNA (0.55) | DRD2BCHEACHEBACE1DRD4 | |
| SCHEMBL1351299 | 0.88 | DRD2 (0.49) | DRD2DRD3DRD4 | |
| SCHEMBL1349520 | 0.88 | DRD2 (0.49) | DRD2BCHEACHEBACE1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2016-02-25 | — | — | US | claimed |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2014-06-12 | — | — | US | claimed |
| US-8673896-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | claimed |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2016-02-25 | — | — | US | disclosed |
| US-9133206-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-8673896-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | GABRA3, GABRB3, GABRA1 | DRD2 56/4885BCHE 1172/4885ACHE 1325/4885 |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | DRD2 56/4885BCHE 1172/4885ACHE 1325/4885 |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | DRD2 56/4885BCHE 1172/4885ACHE 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.